Dantrolene as a treatment option for RYR1-related rhabdomyolysis by Scalco, RS et al.
Category: Advances in the treatment of neuromuscular disorders 
 
Dantrolene as a treatment option for RYR1-related rhabdomyolysis 
Renata Siciliani Scalco1,2, Nicol C. Voermans3, Richard J Piercy4,  Heinz 
Jungbluth5,6,7, Ros Quinlivan1,8 
1) MRC Centre for Neuromuscular Diseases and Department of Molecular 
Neuroscience, University College London (UCL) Institute of Neurology and 
National Hospital for Neurology and Neurosurgery, London, UK  
2) CAPES Foundation, Ministry of Education of Brazil, Brasilia, DF, Brazil  
3) Department of Neurology, Radboud University Medical Center, Nijmegen, The 
Netherlands  
4) Comparative Neuromuscular Diseases Laboratory, Royal Veterinary College, 
London, UK 
5) Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology 
and Neuroscience (IoPPN), King’s College London (KCL), London, UK 
6) Randall Division for Cell and Molecular Biophysics, Muscle Signalling Section, 
King’s College London, London, UK 
7) Department of Paediatric Neurology, Evelina Children’s Hospital, Guy’s & St 
Thomas NHS Foundation Trust, London, UK 
8) Dubowitz Neuromuscular Centre, Great Ormond Street Hospital, London, UK  
 
Background: Mutations in RYR1 lead to various neuromuscular phenotypes including 
rhabdomyolysis (RM). We recently reported the use of oral dantrolene as a prophylactic 
treatment for RYR1-related RM. Here we will report updated data on safety of 
dantrolene in the reported patients and report the dantrolene use in RM-susceptible 
thoroughbred racehorses. 
Methods: Case series. 
Results: Three patients presenting with severe recurrent episodes of RYR1-related RM 
were prescribed 25mg of oral dantrolene up to a maximum of three times a day to be 
taken as required with symptom onset in order to stop progression of RM episodes. P1 
and P2 were on dantrolene for 18 months while P3 continued treatment for 7 years. P1 
reported complete abatement of symptoms within 20-30 minutes of taking dantrolene 
soon after onset of myalgia/cramps. P2 was able to resume symptom-free exercise by 
taking 25mg of dantrolene prior to physical activity. P3 started using dantrolene after 
the second episode of RM. Over a 7-year-period she has suffered fewer additional 
episodes of RM, but with less markedly elevated CK levels. No significant side-effects 
were reported and the liver function remained normal in all 3 patients. 
Dantrolene is highly efficacious for rhabdomyolysis-susceptible Thoroughbred 
racehorses (2 to 3 mg/kg) in training, administrated orally 60-90 minutes prior to 
exercise. Typically, the drug is used in RM-susceptible animals, when training levels are 
increasing in intensity or following a period of rest and its use is withdrawn prior to 
racing. 
Conclusion: Short term intermittent use of low dose dantrolene appeared to be 
beneficial in three patients with recurrent RYR1-related rhabdomyolysis without undue 
side-effects. Benefits of dantrolene therapy have also been reported in RM-susceptible 
thoroughbred racehorses. Undertaking a RCT to assess risks and benefits of dantrolene 
in this group of patients more systematically could help to evaluate the role of 
Dantrolene in RYR1-related RM. 
 
 
